Abstract
Nilotinib (Tasigna) and dasatinib (Sprycel) are second-generation tyrosine kinase inhibitors that are approved for second-line treatment of patients with chronic myeloid leukemia (CML) who are intolerant of, or resistant to, the first-generation inhibitor imatinib. To assess the efficacy and safety of nilotinib and dasatinib as initial treatments for patients with newly diagnosed, chronic-phase CML, investigators conducted two industry-supported, multicenter phase III trials in which the agents were compared with standard imatinib therapy. In the nilotinib study, 846 patients were randomized to receive one of three treatments: lower-dose nilotinib (300 mg orally twice daily), higher-dose nilotinib (400 …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
